27070 Federal Register / Vol. 83, No. 112 / Monday, June 11, 2018 / Notices 

www.regulations.gov. Follow the 

instructions for submitting comments in 

section III below. The docket number is 

USTR–2018–0014. For alternatives to 

on-line submissions, please contact 

Sandy McKinzy at (202) 395–9483. 

FOR FURTHER INFORMATION CONTACT: 

Assistant General Counsel Juli Schwartz 

at (202) 395–3150. 

SUPPLEMENTARY INFORMATION: 

I. Background 

USTR is providing notice that Korea 

has requested consultations pursuant to 

the WTO Understanding on Rules and 

Procedures Governing the Settlement of 

Disputes (DSU), the General Agreement 

on Tariffs and Trade 1994, and the 

Agreement on Safeguards (SGA). If 

these consultations do not resolve the 

matter, Korea could request that the 

WTO establish a dispute settlement 

panel pursuant to the DSU, which 

would hold its meetings in Geneva, 

Switzerland, and issue a report on its 

findings. 

II. Major Issues Raised by Korea 

On May 14, 2018, Korea requested 

consultations concerning the safeguard 

measure in effect pursuant to 

Proclamation 9594 of January 23, 

2018—To Facilitate a Positive 

Adjustment to Competition from 

Imports of Large Residential Washers, 

83 FR 3553 (Jan. 25, 2018). Korea alleges 

that the United States’ safeguard action 

is inconsistent with Articles I:1, II, X:3, 

and XIX:1 of the GATT 1994 and 

Articles 2.1, 2.2, 3.1, 3.2, 4.1, 4.2, 5.1, 

7.1, 7.4, 8.1, 12.1, 12.2, and 12.3 of the 

SGA. 

III. Public Comments: Requirements for 

Submissions 

USTR invites written comments 

concerning the issues raised in this 

dispute. All submissions must be in 

English and sent electronically via 

www.regulations.gov. To submit 

comments via www.regulations.gov, 

enter docket number USTR–2018–0014 

on the home page and click ‘‘search.’’ 

The site will provide a search-results 

page listing all documents associated 

with this docket. Find a reference to this 

notice by selecting ‘‘notice’’ under 

‘‘document type’’ on the left side of the 

search-results page, and click on the 

link entitled ‘‘comment now!’’ For 

further information on using the 

www.regulations.gov website, please 

consult the resources provided on the 

website by clicking on ‘‘How to Use 

Regulations.gov’’ on the bottom of the 

home page. 

The www.regulations.gov website 

allows users to provide comments by 

filling in a ‘‘type comment’’ field, or by 

attaching a document using an ‘‘upload 

file’’ field. USTR prefers that comments 

be provided in an attached document. If 

a document is attached, it is sufficient 

to type ‘‘see attached’’ in the ‘‘type 

comment’’ field. USTR prefers 

submissions in Microsoft Word (.doc) or 

Adobe Acrobat (.pdf). If the submission 

is in an application other than those 

two, please indicate the name of the 

application in the ‘‘type comment’’ 

field. 

For any comments submitted 

electronically containing business 

confidential information, the file name 

of the business confidential version 

should begin with the characters ‘‘BC’’. 

Any page containing business 

confidential information must be clearly 

marked ‘‘BUSINESS CONFIDENTIAL’’ 

on the top of that page and the 

submission should clearly indicate, via 

brackets, highlighting, or other means, 

the specific information that is business 

confidential. If you request business 

confidential treatment, you must certify 

in writing that disclosure of the 

information would endanger trade 

secrets or profitability, and that the 

information would not customarily be 

released to the public. Filers of 

submissions containing business 

confidential information also must 

submit a public version of their 

comments. The file name of the public 

version should begin with the character 

‘‘P’’. The ‘‘BC’’ and ‘‘P’’ should be 

followed by the name of the person or 

entity submitting the comments or 

rebuttal comments. If these procedures 

are not sufficient to protect business 

confidential information or otherwise 

protect business interests, please contact 

Sandy McKinzy at (202) 395–9483 to 

discuss whether alternative 

arrangements are possible. 

USTR may determine that information 

or advice contained in a comment, other 

than business confidential information, 

is confidential in accordance with 

section 135(g)(2) of the Trade Act of 

1974 (19 U.S.C. 2155(g)(2)). If a 

submitter believes that information or 

advice is confidential, s/he must clearly 

designate the information or advice as 

confidential and mark it as 

‘‘SUBMITTED IN CONFIDENCE’’ at the 

top and bottom of the cover page and 

each succeeding page, and provide a 

non-confidential summary of the 

information or advice. 

Pursuant to section 127(e) of the 

Uruguay Round Agreements Act (19 

U.S.C. 3537(e)), USTR will maintain a 

docket on this dispute settlement 

proceeding, docket number USTR– 

2018–0014, accessible to the public at 

www.regulations.gov. The public file 

will include non-confidential public 

comments USTR receives regarding the 

dispute. If a dispute settlement panel is 

convened, or in the event of an appeal 

of a panel report, USTR will make the 

following documents publicly available 

at www.ustr.gov: The U.S. submissions 

and any non-confidential summaries of 

submissions received from other 

participants in the dispute. If a dispute 

settlement panel is convened, the report 

of the panel, and, in the event of an 

appeal of a panel report, the report of 

the Appellate Body, will also be 

available on the website of the World 

Trade Organization, at www.wto.org. 

Juan Millan, 

Assistant United States Trade Representative 

for Monitoring and Enforcement Office of the 

U.S. Trade Representative. 

[FR Doc. 2018–12447 Filed 6–8–18; 8:45 am] 

BILLING CODE 3290–F8–P 

DEPARTMENT OF TRANSPORTATION 

Federal Motor Carrier Safety 

Administration 

[Docket No. FMCSA–2018–0030] 

Qualification of Drivers; Exemption 

Applications; Diabetes Mellitus 

AGENCY: Federal Motor Carrier Safety 

Administration (FMCSA), DOT. 

ACTION: Notice of applications for 

exemption; request for comments. 

SUMMARY: FMCSA announces receipt of 

applications from 41 individuals for an 

exemption from the prohibition in the 

Federal Motor Carrier Safety 

Regulations (FMCSRs) against persons 

with insulin-treated diabetes mellitus 

(ITDM) operating a commercial motor 

vehicle (CMV) in interstate commerce. If 

granted, the exemptions would enable 

these individuals with ITDM to operate 

CMVs in interstate commerce. 

DATES: Comments must be received on 

or before July 11, 2018. 

ADDRESSES: You may submit comments 

bearing the Federal Docket Management 

System (FDMS) Docket No. FMCSA– 

2018–0030 using any of the following 

methods: 

• Federal eRulemaking Portal: Go to 

http://www.regulations.gov. Follow the 

online instructions for submitting 

comments. 

• Mail: Docket Management Facility; 

U.S. Department of Transportation, 1200 

New Jersey Avenue SE, West Building 

Ground Floor, Room W12–140, 

Washington, DC 20590–0001. 

• Hand Delivery: West Building 

Ground Floor, Room W12–140, 1200 

New Jersey Avenue SE, Washington, 

DC, between 9 a.m. and 5 p.m., e.t., 


daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 112 / Monday, June 11, 2018 / Notices 27071 

Monday through Friday, except Federal 

Holidays. 

• Fax: 1–202–493–2251. 

Instructions: Each submission must 

include the Agency name and the 

docket number(s) for this notice. Note 

that all comments received will be 

posted without change to http://

www.regulations.gov, including any 

personal information provided. Please 

see the Privacy Act heading below for 

further information. 

Docket: For access to the docket to 

read background documents or 

comments, go to http://

www.regulations.gov at any time or 

Room W12–140 on the ground level of 

the West Building, 1200 New Jersey 

Avenue SE, Washington, DC, between 9 

a.m. and 5 p.m., e.t., Monday through 

Friday, except Federal holidays. The 

FDMS is available 24 hours each day 

e.t., 365 days each year. If you want 

acknowledgment that we received your 

comments, please include a selfaddressed, stamped envelope or 

postcard or print the acknowledgement 

page that appears after submitting 

comments online. 

Privacy Act: In accordance with 5 

U.S.C. 553(c), DOT solicits comments 

from the public to better inform its 

rulemaking process. DOT posts these 

comments, without edit, including any 

personal information the commenter 

provides, to http://www.regulations.gov, 

as described in the system of records 

notice (DOT/ALL–14 FDMS), which can 

be reviewed at http://www.dot.gov/ 

privacy. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Christine A. Hydock, Chief, Medical 

Programs Division, (202) 366–4001, 

fmcsamedical@dot.gov, FMCSA, 

Department of Transportation, 1200 

New Jersey Avenue SE, Room W64–224, 

Washington, DC 20590–0001. Office 

hours are 8:30 a.m. to 5 p.m., e.t., 

Monday through Friday, except Federal 

holidays. If you have questions 

regarding viewing or submitting 

material to the docket, contact Docket 

Services, telephone (202) 366–9826. 

SUPPLEMENTARY INFORMATION: 

I. Background 

Under 49 U.S.C. 31136(e) and 31315, 

FMCSA may grant an exemption from 

the FMCSRs for a five-year period if it 

finds ‘‘such exemption would likely 

achieve a level of safety that is 

equivalent to or greater than the level 

that would be achieved absent such 

exemption.’’ The statute also allows the 

Agency to renew exemptions at the end 

of the five-year period. FMCSA grants 

exemptions from the FMCSRs for a twoyear period to align with the maximum 

duration of a driver’s medical 

certification. 

The 41 individuals listed in this 

notice have requested an exemption 

from the diabetes prohibition in 49 CFR 

391.41(b)(3). Accordingly, the Agency 

will evaluate the qualifications of each 

applicant to determine whether granting 

the exemption will achieve the required 

level of safety mandated by statute. 

The physical qualification standard 

for drivers regarding diabetes found in 

49 CFR 391.41(b)(3) states that a person 

is physically qualified to drive a CMV 

if that person has no established 

medical history or clinical diagnosis of 

diabetes mellitus currently requiring 

insulin for control. The Agency 

established the current requirement for 

diabetes in 1970 because several risk 

studies indicated that drivers with 

diabetes had a higher rate of crash 

involvement than the general 

population. 

FMCSA established its diabetes 

exemption program, based on the 

Agency’s July 2000 study entitled ‘‘A 

Report to Congress on the Feasibility of 

a Program to Qualify Individuals with 

Insulin-Treated Diabetes Mellitus to 

Operate in Interstate Commerce as 

Directed by the Transportation Act for 

the 21st Century.’’ The report concluded 

that a safe and practicable protocol to 

allow some drivers with ITDM to 

operate CMVs is feasible. The 

September 3, 2003 (68 FR 52441), 

Federal Register notice in conjunction 

with the November 8, 2005 (70 FR 

67777), Federal Register notice provides 

the current protocol for allowing such 

drivers to operate CMVs in interstate 

commerce. 

FMCSA notes that section 4129 of the 

Safe, Accountable, Flexible and 

Efficient Transportation Equity Act: A 

Legacy for Users requires the Secretary 

to revise its diabetes exemption program 

established on September 3, 2003 (68 FR 

52441). The revision must provide for 

individual assessment of drivers with 

diabetes mellitus, and be consistent 

with the criteria described in section 

4018 of the Transportation Equity Act 

for the 21st Century (49 U.S.C. 31305). 

Section 4129 requires: (1) Elimination of 

the requirement for three years of 

experience operating CMVs while being 

treated with insulin; and (2) 

establishment of a specified minimum 

period of insulin use to demonstrate 

stable control of diabetes before being 

allowed to operate a CMV. 

In response to section 4129, FMCSA 

made immediate revisions to the 

diabetes exemption program established 

by the September 3, 2003 notice. 

FMCSA discontinued use of the threeyear driving experience and fulfilled the 

requirements of section 4129 while 

continuing to ensure that operation of 

CMVs by drivers with ITDM will 

achieve the requisite level of safety 

required of all exemptions granted 

under 49 U.S.C. 31136 (e). Section 

4129(d) also directed FMCSA to ensure 

that drivers of CMVs with ITDM are not 

held to a higher standard than other 

drivers, with the exception of limited 

operating, monitoring and medical 

requirements that are deemed medically 

necessary. The FMCSA concluded that 

all of the operating, monitoring and 

medical requirements set out in the 

September 3, 2003, notice, except as 

modified, were in compliance with 

section 4129(d). Therefore, all of the 

requirements set out in the September 3, 

2003, notice, except as modified by the 

notice in the Federal Register on 

November 8, 2005 (70 FR 67777), 

remain in effect. 

II. Qualifications of Applicants 

Gerardo Arredondo 

Mr. Arredondo, 56, has had ITDM 

since 2011. His endocrinologist 

examined him in 2017 and certified that 

he has had no severe hypoglycemic 

reactions resulting in loss of 

consciousness, requiring the assistance 

of another person, or resulting in 

impaired cognitive function that 

occurred without warning in the past 12 

months and no recurrent (two or more) 

severe hypoglycemic episodes in the 

last five years. His endocrinologist 

certifies that Mr. Arredondo 

understands diabetes management and 

monitoring, has stable control of his 

diabetes using insulin, and is able to 

drive a CMV safely. Mr. Arredondo 

meets the requirements of the vision 

standard at 49 CFR 391.41(b)(10). His 

ophthalmologist examined him in 2017 

and certified that he has stable 

nonproliferative diabetic retinopathy. 

He holds a Class A CDL from Texas. 

Ammar H. Atieh 

Mr. Atieh, 22, has had ITDM since 

2004. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Atieh understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Atieh meets the requirements 

of the vision standard at 49 CFR 


daltland on DSKBBV9HB2PROD with NOTICES
27072 Federal Register / Vol. 83, No. 112 / Monday, June 11, 2018 / Notices 

391.41(b)(10). His ophthalmologist 

examined him in 2018 and certified that 

he does not have diabetic retinopathy. 

He holds an operator’s license from New 

Jersey. 

Robert P. Baker, Jr. 

Mr. Baker, 37, has had ITDM since 

2002. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Baker understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Baker meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His 

ophthalmologist examined him in 2018 

and certified that he has stable 

nonproliferative diabetic retinopathy. 

He holds an operator’s from Indiana. 

Jose A. Barron 

Mr. Barron, 62, has had ITDM since 

2008. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Barron understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Barron meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds a Class A CDL from Texas. 

Michael D. Cash 

Mr. Cash, 51, has had ITDM since 

2017. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Cash understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Cash meets the requirements 

of the vision standard at 49 CFR 

391.41(b)(10). His optometrist examined 

him in 2018 and certified that he does 

not have diabetic retinopathy. He holds 

an operator’s license from New York. 

Travis A. Chandler 

Mr. Chandler, 31, has had ITDM since 

1998. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Chandler understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Chandler meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2018 and certified that 

he does not have diabetic retinopathy. 

He holds an operator’s license from 

Tennessee. 

Curtis D. Dement 

Mr. Dement, 63, has had ITDM since 

2018. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Dement understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Dement meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2018 and certified that 

he does not have diabetic retinopathy. 

He holds a Class A CDL from North 

Dakota. 

Mark A. Duncan 

Mr. Duncan, 56, has had ITDM since 

2016. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Duncan understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Duncan meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2018 and certified that 

he does not have diabetic retinopathy. 

He holds a Class A CDL from Kansas. 

Hugh J. Gallagher 

Mr. Gallagher, 57, has had ITDM since 

2016. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Gallagher understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Gallagher meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His 

ophthalmologist examined him in 2017 

and certified that he does not have 

diabetic retinopathy. He holds a Class A 

CDL from Indiana. 

Charles Gant 

Mr. Gant, 48, has had ITDM since 

2016. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Gant understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Gant meets the requirements 

of the vision standard at 49 CFR 

391.41(b)(10). His optometrist examined 

him in 2017 and certified that he does 

not have diabetic retinopathy. He holds 

an operator’s license from Pennsylvania. 

Gary D. Gudeman 

Mr. Gudeman, 60, has had ITDM 

since 2013. His endocrinologist 

examined him in 2018 and certified that 

he has had no severe hypoglycemic 

reactions resulting in loss of 

consciousness, requiring the assistance 

of another person, or resulting in 

impaired cognitive function that 

occurred without warning in the past 12 

months and no recurrent (two or more) 

severe hypoglycemic episodes in the 

last five years. His endocrinologist 


daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 112 / Monday, June 11, 2018 / Notices 27073 

certifies that Mr. Gudeman understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Gudeman meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His 

ophthalmologist examined him in 2018 

and certified that he does not have 

diabetic retinopathy. He holds an 

operator’s license from Indiana. 

Richard D. Hawkins 

Mr. Hawkins, 43, has had ITDM since 

2007. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Hawkins understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Hawkins meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His 

ophthalmologist examined him in 2017 

and certified that he has stable 

nonproliferative diabetic retinopathy. 

He holds an operator’s license from 

Indiana. 

Michael A. Hayes 

Mr. Hayes, 43, has had ITDM since 

2018. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Hayes understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Hayes meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds a Class A CDL from North 

Carolina.4 

Brent M. Howard 

Mr. Howard, 55, has had ITDM since 

2017. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Howard understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Howard meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His 

ophthalmologist examined him in 2018 

and certified that he has stable 

nonproliferative diabetic retinopathy. 

He holds a Class A CDL from Iowa. 

Herbert O. Jenkins 

Mr. Jenkins, 55, has had ITDM since 

1992. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Jenkins understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Jenkins meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His 

ophthalmologist examined him in 2018 

and certified that he has stable 

proliferative diabetic retinopathy. He 

holds an operator’s license from 

Kentucky. 

Scott A. Kiel 

Mr. Kiel, 52, has had ITDM since 

2018. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Kiel understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Kiel meets the requirements 

of the vision standard at 49 CFR 

391.41(b)(10). His optometrist examined 

him in 2018 and certified that he does 

not have diabetic retinopathy. He holds 

a Class A CDL from North Dakota. 

Barry T. Koch 

Mr. Koch, 59, has had ITDM since 

2010. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Koch understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Koch meets the requirements 

of the vision standard at 49 CFR 

391.41(b)(10). His ophthalmologist 

examined him in 2018 and certified that 

he has stable nonproliferative diabetic 

retinopathy. He holds an operator’s 

license from Pennsylvania. 

Jose Lares 

Mr. Lares, 59, has had ITDM since 

2018. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Lares understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Lares meets the requirements 

of the vision standard at 49 CFR 

391.41(b)(10). His ophthalmologist 

examined him in 2018 and certified that 

he does not have diabetic retinopathy. 

He holds a Class B CDL from Arizona. 

John A. Larson 

Mr. Larson, 67, has had ITDM since 

2011. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Larson understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Larson meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2018 and certified that 

he does not have diabetic retinopathy. 

He holds a Class A CDL from 

Minnesota. 

Brian T. Lewis 

Mr. Lewis, 52, has had ITDM since 

2017. His endocrinologist examined him 


daltland on DSKBBV9HB2PROD with NOTICES
27074 Federal Register / Vol. 83, No. 112 / Monday, June 11, 2018 / Notices 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Lewis understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Lewis meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2018 and certified that 

he does not have diabetic retinopathy. 

He holds a Class B CDL from California. 

Mark J. Longtin 

Mr. Longtin, 66, has had ITDM since 

2017. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Longtin understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Longtin meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds an operator’s license from 

South Dakota. 

Christopher A. Marquette 

Mr. Marquette, 37, has had ITDM 

since 2016. His endocrinologist 

examined him in 2018 and certified that 

he has had no severe hypoglycemic 

reactions resulting in loss of 

consciousness, requiring the assistance 

of another person, or resulting in 

impaired cognitive function that 

occurred without warning in the past 12 

months and no recurrent (two or more) 

severe hypoglycemic episodes in the 

last five years. His endocrinologist 

certifies that Mr. Marquette understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Marquette meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2018 and certified that 

he does not have diabetic retinopathy. 

He holds a Class A CDL from 

Minnesota. 

Kasey J. Martin 

Mr. Martin, 28, has had ITDM since 

2010. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Martin understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Martin meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds an operator’s license from 

Indiana. 

David A. Martin 

Mr. Martin, 60, has had ITDM since 

2017. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Martin understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Martin meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His 

ophthalmologist examined him in 2018 

and certified that he does not have 

diabetic retinopathy. He holds a Class A 

CDL from Illinois. 

Ryan J. Matthews 

Mr. Matthews, 39, has had ITDM 

since 1995. His endocrinologist 

examined him in 2018 and certified that 

he has had no severe hypoglycemic 

reactions resulting in loss of 

consciousness, requiring the assistance 

of another person, or resulting in 

impaired cognitive function that 

occurred without warning in the past 12 

months and no recurrent (two or more) 

severe hypoglycemic episodes in the 

last five years. His endocrinologist 

certifies that Mr. Matthews understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Matthews meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His 

ophthalmologist examined him in 2018 

and certified that he has stable 

nonproliferative diabetic retinopathy. 

He holds an operator’s license from 

Ohio. 

Gion H. Mersha 

Mr. Mersha, 44, has had ITDM since 

2017. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Mersha understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Mersha meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2018 and certified that 

he does not have diabetic retinopathy. 

He holds an operator’s license from 

Iowa. 

Phillip A. Nass 

Mr. Nass, 65, has had ITDM since 

2016. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Nass understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Nass meets the requirements 

of the vision standard at 49 CFR 

391.41(b)(10). His optometrist examined 

him in 2017 and certified that he does 

not have diabetic retinopathy. He holds 

a Class A CDL from Wisconsin. 

Frank T. Piper, Jr. 

Mr. Piper, 65, has had ITDM since 

2013. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Piper understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 


daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 112 / Monday, June 11, 2018 / Notices 27075 

safely. Mr. Piper meets the requirements 

of the vision standard at 49 CFR 

391.41(b)(10). His ophthalmologist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds an operator’s license from 

Connecticut. 

James P. Renaud 

Mr. Renaud, 49, has had ITDM since 

2017. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Renaud understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Renaud meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His 

ophthalmologist examined him in 2018 

and certified that he has stable 

nonproliferative diabetic retinopathy. 

He holds a Class A CDL from New 

Hampshire. 

Charles D. Robison 

Mr. Robison, 56, has had ITDM since 

2017. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Robison understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Robison meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2018 and certified that 

he does not have diabetic retinopathy. 

He holds a Class A CDL from Iowa. 

Michael A. Roosa 

Mr. Roosa, 53, has had ITDM since 

2016. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Roosa understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Roosa meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His 

ophthalmologist examined him in 2017 

and certified that he does not have 

diabetic retinopathy. He holds an 

operator’s license from Massachusetts. 

Alan Sang 

Mr. Sang, 48, has had ITDM since 

2015. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Sang understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Sang meets the requirements 

of the vision standard at 49 CFR 

391.41(b)(10). His ophthalmologist 

examined him in 2018 and certified that 

he does not have diabetic retinopathy. 

He holds a Class B CDL from Florida. 

James M. Sanicola 

Mr. Sanicola, 61, has had ITDM since 

2017. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Sanicola understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Sanicola meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds a Class B CDL from Wisconsin. 

Michael J. Torrez 

Mr. Torrez, 58, has had ITDM since 

2018. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Torrez understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Torrez meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2018 and certified that 

he does not have diabetic retinopathy. 

He holds a Class A CDL from 

Wisconsin. 

Gerard N. Tremblay, Jr. 

Mr. Tremblay, 48, has had ITDM since 

2010. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Tremblay understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Tremblay meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2018 and certified that 

he does not have diabetic retinopathy. 

He holds an operator’s license from 

Massachusetts. 

John H. Turner 

Mr. Turner, 73, has had ITDM since 

2017. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Turner understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Turner meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2018 and certified that 

he does not have diabetic retinopathy. 

He holds a Class A CDL from Georgia. 

Marcus D. Wade 

Mr. Wade, 24, has had ITDM since 

2013. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 


daltland on DSKBBV9HB2PROD with NOTICES
27076 Federal Register / Vol. 83, No. 112 / Monday, June 11, 2018 / Notices 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Wade understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Wade meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds an operator’s license from 

Illinois. 

James A. White 

Mr. White, 55, has had ITDM since 

2013. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. White understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. White meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2018 and certified that 

he does not have diabetic retinopathy. 

He holds a Class A CDL from Louisiana. 

Theodore M. Wicks 

Mr. Wicks, 66, has had ITDM since 

2016. His endocrinologist examined him 

in 2018 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Wicks understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Wicks meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2017 and certified that 

he does not have diabetic retinopathy. 

He holds a Class A CDL from Wyoming. 

Raymond L. Williamson 

Mr. Williamson, 66, has had ITDM 

since 2017. His endocrinologist 

examined him in 2017 and certified that 

he has had no severe hypoglycemic 

reactions resulting in loss of 

consciousness, requiring the assistance 

of another person, or resulting in 

impaired cognitive function that 

occurred without warning in the past 12 

months and no recurrent (two or more) 

severe hypoglycemic episodes in the 

last five years. His endocrinologist 

certifies that Mr. Williamson 

understands diabetes management and 

monitoring, has stable control of his 

diabetes using insulin, and is able to 

drive a CMV safely. Mr. Williamson 

meets the requirements of the vision 

standard at 49 CFR 391.41(b)(10). His 

optometrist examined him in 2017 and 

certified that he does not have diabetic 

retinopathy. He holds a Class A CDL 

from Illinois. 

Steve B. Winger 

Mr. Winger, 60, has had ITDM since 

2012. His endocrinologist examined him 

in 2017 and certified that he has had no 

severe hypoglycemic reactions resulting 

in loss of consciousness, requiring the 

assistance of another person, or 

resulting in impaired cognitive function 

that occurred without warning in the 

past 12 months and no recurrent (two or 

more) severe hypoglycemic episodes in 

the last five years. His endocrinologist 

certifies that Mr. Winger understands 

diabetes management and monitoring, 

has stable control of his diabetes using 

insulin, and is able to drive a CMV 

safely. Mr. Winger meets the 

requirements of the vision standard at 

49 CFR 391.41(b)(10). His optometrist 

examined him in 2018 and certified that 

he does not have diabetic retinopathy. 

He holds a Class A CDL from Montana. 

III. Request for Comments 

In accordance with 49 U.S.C. 31136(e) 

and 31315, FMCSA requests public 

comment from all interested persons on 

the exemption petitions described in 

this notice. We will consider all 

comments received before the close of 

business on the closing date indicated 

in the dates section of the notice. 

IV. Submitting Comments 

You may submit your comments and 

material online or by fax, mail, or hand 

delivery, but please use only one of 

these means. FMCSA recommends that 

you include your name and a mailing 

address, an email address, or a phone 

number in the body of your document 

so that FMCSA can contact you if there 

are questions regarding your 

submission. 

To submit your comment online, go to 

http://www.regulations.gov and in the 

search box insert the docket number 

FMCSA–2018–0030 and click the search 

button. When the new screen appears, 

click on the blue ‘‘Comment Now!’’ 

button on the right hand side of the 

page. On the new page, enter 

information required including the 

specific section of this document to 

which each comment applies, and 

provide a reason for each suggestion or 

recommendation. If you submit your 

comments by mail or hand delivery, 

submit them in an unbound format, no 

larger than 81⁄2 by 11 inches, suitable for 

copying and electronic filing. If you 

submit comments by mail and would 

like to know that they reached the 

facility, please enclose a stamped, selfaddressed postcard or envelope. 

We will consider all comments and 

materials received during the comment 

period. FMCSA may issue a final 

determination at any time after the close 

of the comment period. 

V. Viewing Comments and Documents 

To view comments, as well as any 

documents mentioned in this preamble, 

go to http://www.regulations.gov and in 

the search box insert the docket number 

FMCSA–2018–0030 and click ‘‘Search.’’ 

Next, click ‘‘Open Docket Folder’’ and 

you will find all documents and 

comments related to this notice. 

Issued on: June 5, 2018. 

Larry W. Minor, 

Associate Administrator for Policy. 

[FR Doc. 2018–12473 Filed 6–8–18; 8:45 am] 

BILLING CODE 4910–EX–P 

DEPARTMENT OF TRANSPORTATION 

Pipeline and Hazardous Materials 

Safety Administration 

Hazardous Materials: Notice of 

Applications for Special Permits 

AGENCY: Pipeline and Hazardous 

Materials Safety Administration 

(PHMSA), DOT. 

ACTION: List of applications for 

modification of special permits. 

SUMMARY: In accordance with the 

procedures governing the application 

for, and the processing of, special 

permits from the Department of 

Transportation’s Hazardous Material 

Regulations, notice is hereby given that 

the Office of Hazardous Materials Safety 

has received the application described 

herein. 

DATES: Comments must be received on 

or before June 26, 2018. 

ADDRESSES: Record Center, Pipeline and 

Hazardous Materials Safety 

Administration, U.S. Department of 

Transportation, Washington, DC 20590. 

Comments should refer to the 

application number and be submitted in 

triplicate. If confirmation of receipt of 

comments is desired, include a selfaddressed stamped postcard showing 

the special permit number. 


daltland on DSKBBV9HB2PROD with NOTICES